Expertise
We have a wealth of expertise at the global, continental, national, regional, local, and hospital level.
We have an understanding of the patient-centered and market access environments across the globe – our work often covers a global, US or European scope, and in addition, we also have extensive experience in supporting clients with projects in emerging markets throughout the world including Canada, China, India, Japan, Mexico, South Africa, South Korea, and many other countries throughout Africa, Central and South America, Asia and Australasia.
Health Economics & Data Analysis
We have a dedicated team of commercially-focused health economists and statisticians who interrogate, analyse and present economic and clinical data to support your product’s value proposition and steer it towards market access success. With vast experience across a broad range of project types, we use innovative research techniques to ensure our insights are clear and engaging. Expertise in R modelling as well as Excel, and the ability to develop standardized model structures with integrated software facilities for data manipulation, calculation and visualization, means we can provide tailored, flexible solutions to meet individual client and project needs.
To find out our expertise, click on one of the areas below
SPM case study – Hannah chased re: model outputs/results to be included (following LH email)
LEARN MORE
Elicitation of health state utilities across six global markets
LEARN MORE
Training and upskilling a client team on health economics
LEARN MORE
Defining the wider burden of illness to support the launch of a breakthrough oncology therapy in Europe
LEARN MORE
Understanding and communicating costs of the overall patient treatment pathway
LEARN MORE
Elicitation of health state disutilities associated with once-daily versus once-weekly injectable therapies in T2DM
LEARN MORE
Early cost-utility model to support product positioning and future HTA submissions
LEARN MORE
A network meta-analysis of randomised controlled trials in dementia with Lewy bodies
LEARN MORE
Model validation: Providing an external perspective to optimize economic modelling
LEARN MORE
Assessing the budget impact and cost-effectiveness of a treatment for a rare disease
LEARN MORE
Budget impact model to support inclusion of both adult and pediatric patients for an innovative oncology treatment
LEARN MORE
Key publications
- Karakusevic A, Devaney P, Enstone A, Kanibir N, Hartwig S, Da Silva Carias C. The burden of rotavirus-associated acute gastroenteritis in the elderly: Assessment of the epidemiology in the context of universal childhood vaccination programs. Expert Review of Vaccines, 2022 Jul;21(7):929-940
- Kolobova I, Nyaku MK, Karakusevic A, Bridge D, Fotheringham I, O’Brien M. Burden of vaccine-preventable diseases among at-risk adult populations in the US. Human Vaccines and Immunotherapeutics, Vol 18, Issue 5, 2022
- Gerard McCaughey, Alasdair MacCulloch, Lisa Bashorum, Owen Evans, Ashley C. Humphries, Richard Perry. Burden associated with Fabry Disease and its treatment in 12- to 15-year-olds: Results from an international survey. BMJ, Archives of Disease in Childhood 2022; 107:A201-A202
- McEwan P, Baker-Knight J, Ásbjörnsdóttir B, Yi Y, Fox A, Wyn R. Disutility of injectable therapies in obesity and type 2 diabetes mellitus: General population preferences in the UK, Canada, and China.Eur J Health Econ (2022)
- Yeo S, Holl K, Peñaherrera N, Wissinger U, Anstee K, Wyn R. Burden of male hypogonadism and major comorbidities, and the clinical, economic, and humanistic benefits of testosterone therapy: A narrative review. Clinicoecon Outcomes Res. 2021; 13:31-38
- Hughes R, Swales O, Lucherini S. Modelling the resource utilisation difference of using subcutaneous and intravenous administration of Rituximab within chemotherapy for the treatment of B-cell lymphoma. Value in Health, Vol. 23, Supplement 1, S35-S36, 2020
- Thacker K, Raman J, McLean T, Said J, Oliver L, Gore J. Understanding the economic burden of treating low-grade upper tract urothelial cancer in the United States. Urology Practice. 2020 Jun 9:10-97
- Tahami Monfared A, Desai M, Hughes R, Lucherini S, Yi Y, Perry R. Treatment options for dementia with lewy bodies: A network meta-analysis of randomised control trials. Neurol Ther, 9, 521–534 (2020)
- Spencer C, Anstee K, Yeo S, Holl K, Wessinger-Grafenhahn U. Understanding the economic burden of comorbidities associated with male hypogonadism: A cost model in England. Value in Health, Vol. 23, Supplement 1, S152, 2020
- Tremblay G, Rousseau B, Marquis M, Beaubois C, Sauvageau G, Hébert J. Cost-effectiveness analysis of a HMGA2 prognostic test for acute myeloid leukaemia in a Canadian setting. Appl Health Econ Health Policy, 17, 827–839 (2019)
- Tahami Monfared AA, Meier G, Perry R, Joe D. Burden of disease and current management of dementia with lewy bodies: A literature review Neurol Ther 8, 289–305 (2019)
- Perry R, Braileanu G, Palmer T, Stevens P. The economic burden of pediatric asthma in the United States: Literature review of current evidence. PharmacoEconomics, 37, 155–167 (2019)
- Forster R, Ratcliffe A, Lewis M, Crossley A, Lopez Bastida J, Dunlop W. Cost–utility analysis of an intervention designed to reduce the critical handling error of insufficient inspiratory effort. Eur J Health Econ (2018), 19: 1303
- Usmani OS, Lavorini F, Marshall J, Dunlop W, Heron L, Farrington E, Dekhuijzen R. Critical inhaler errors in asthma and COPD: A systematic review of impact on health economics. Respiratory Research 2018, 19:10
- Enstone A, Greaney M, Povsic M, Wyn R, Penrod J, Yuan Y. The economic burden of small cell lung cancer: A systematic review of the literature. PharmacoEconomics Open (2018) 2:125–139
- Wu E, Pellissier J, Bellanca L, Normand R, Hughes R, Ratcliffe A. A contextual model for evaluating the value of multi-indication drugs. International Journal of Technology Assessment in Health Care, 34(S1), 18-19 (2018)
- Hulin C, Hansen T, Heron L, Pughe R, Streetly M, Plate A, Perkins S, Morgan K, Tinel A, Rodrigues F, Ramasamy K. Living with the burden of relapse in multiple myeloma from the patient and physician perspective. Leukaemia Research 59 (2017) 75-84
- Farrington E, Saunders A, Heron L, Dunlop W. FP/FORM versus FP/SAL within clinical practice: An updated budget impact analysis in asthma. Advances in Therapy, 33, 794–806 (2016)
- Odlaug BL, Gual A, DeCourcy J, Perry R, Pike J, Heron L, Rehm J. Alcohol dependence, co-occurring conditions and attributable burden. Alcohol and Alcoholism, Vol 51, Issue 2, 201–209 (2016)
- Rousseau B, Johnson B, Topachevskyi O, Volovyk A. Web-based budget impact and pricing scenarios planning model: Example from the United Kingdom. Value in Health 2016, Volume 19, Issue 3, A79
- Enstone A, Panter C, Greaney MH, Bennett B, Penrod JR, Yuan Y. The societal and humanistic burden of small cell lung cancer (SCLC): A systematic review of societal impact and health-related quality of life (HRQoL) literature. Value in Health, 19(7), A748 (2016)
- Nicolai J, Torvinen S, Howard DJ, Miles R, Greaney MH, Comberiati U, Plich A. The budget impact of an inhaler with improved features compared to Spiriva® Handihaler® for the management of chronic obstructive pulmonary disease (COPD) in the UK: Estimated impact on unscheduled healthcare costs and inhaler satisfaction. Value in Health 2015 Nov;18(7):A497
- Nicolai J, Torvinen S, Miles R, Greaney MH, Howard DJ, Plich A. The potential societal cost benefits of increasing patient satisfaction by using an inhaler with improved features compared to Spiriva® Handihaler® for the management of chronic obstructive pulmonary disease (COPD) in the UK. Value in Health 2015; 18(7):A500
- Fletcher M, Jha A, Dunlop W, Heron L, Wolfram V, Van der Molen T, Price D. Patient reported burden of asthma on resource use and productivity across 11 countries in Europe. Adv Ther. 2015 Apr;32(4):370-80
- Gater A, Kitchen H, Heron L, Pollard C, Håkan-Bloch J, Højbjerre L, Bekker Hansen B, Strandberg-Larsen M. Development of a conceptual model evaluating the humanistic and economic burden of Crohn’s disease: Implications for patient-reported outcomes measurement and economic evaluation. Expert Rev Pharmacoecon Outcomes Res 2015, 15(4):643-56
- Fletcher M, Dunlop W, Jha A, Heron L, Van der Molen T, Price D. Burden of asthma on resource and productivity in 6 European countries. Eur Respir J 2014; 44(50):3816
- Price D, Dunlop W, Jha A, Heron L, Van der Molen T, Fletcher M. Burden of asthma on resource and productivity in distinct patient clusters. Eur Respir J 2014; 44(58):3020
- Dunlop W, Heron L, Fox G, Greaney M. Budget impact analysis of a fixed-dose combination of fluticasone propionate and formoterol fumarate (FP/FORM) in a pressurized metered-dose inhaler (pMDI) for asthma. Adv Ther 2013; 30(10);933-944
- Dunlop W, Iqbal I, Khan I, Ouwens M, Heron L. Cost-effectiveness of modified-release prednisone in the treatment of moderate to severe rheumatoid arthritis with morning stiffness based on directly elicited public preference values. Clinic Econ Outcomes 2013;5:555-564
- Tolley K, Goad C, Yi Y, Maroudas P, Thompson G. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. European Journal of Health Economics, 14, 749–759 (2013)
- Kitchen H, Rofail D, Heron L, Sacco P. Cognitive impairment associated with schizophrenia: A review of the humanistic burden. Adv Ther 2012;29:148
- Gater A, Kitchen H, Heron L, Hansen BB, Højbjerre L, Strandberg-Larsen M. Using clinical outcome assessments and economic data to facilitate patient access in rheumatoid arthritis. Value Health 2012;15:A484
- Yi Y, Lindemann M, Colligs A, Snowball C. Economic burden of neural tube defects and impact of prevention with folic acid: A literature review. Eur J Pediatr 2011; 170:1391–1400
- Yi Y, Chouaid C, Vergnenegre A, Bischoff HG, Bergman G, Walzer S, Philips Z. Mixed treatment comparison of bevacizumab-based therapies relative to doublet-chemotherapy combinations to estimate the relative efficacy in progression-free survival for treatment of first-line advanced or metastatic non-small cell lung cancer (NSCLC). Value in Health 2010; 13 (7): A253-A254
- Verdian L, Yi Y. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom. Seizure 2010; 19(1):1-11
- Yi Y, Philips Z, Bergman G, Burslem K. Economic models in type 2 diabetes. Current Medical Research & Opinion 2010; 26 (9): 2105–2118
- Yi Y, Maynard A. Medical savings accounts in China. Euro Observer 2008; 10(4):12-14
- Yi Y, Verdian L, Oyee J, Tolley K, Heyes A. Eliciting utility scores for health states associated with Lennox-Gastaut Syndrome. Value in Health 2008; 11 (6): A606
- Yi Y, Verdian L, Jansen JP. Rufinamide in the adjunctive treatment of Lennox-Gastaut Syndrome (LGS): A cost effectiveness analysis. Value in Health 2008; 11 (6): A605
Conference presentations
- Suokas A, Yi Y, Hirst A. Cost-effectiveness of earlier whole-genome sequencing in rare genetic childhood epilepsy. Poster presented at ISPOR, November 2022
- Hughes R, Mountain G, Beyer A, Aguiar-Ibáñez R, Chaker O, Tourret M, Paoli L, Bensimon L. Health Impact projection of Anti-PD-(L)1 inhibitors in 13 cancer indications in France. Poster presented at ISPOR, November 2022
- Ktena D, Dalakaki E, Dimitriadis I, Mountain G, Hughes R, Clarke-Melville S, Roediger A, Naoum P, Athanasakis K. Assessing the impact of Anti-PD-(L)1 inhibitors on cancer care health and budget in Greece. Poster presented at ISPOR, November 2022
- Zhou A, Yi Y. Digital health interventions: A review of economic evaluation guidelines from health technology assessment agencies. Poster presented at ISPOR, November 2022
- Hughes R, Hirst A, Brandolini G. Inclusion of environmental sustainability in the economic analysis of healthcare interventions: A review of policy approaches. Poster presented at ISPOR, November 2022
- Bencina G, Chami N, Hughes R, Weston G, Baxter C, Salomonsson S. Assessing impact of kidney cancer-related premature mortality and productivity loss in Greece and Portugal. Poster presented at ISPOR, November 2022
- Bencina G, Chami N, Hughes R, Weston G, Baxter C, Karamousouli E, Salomonsson S. Triple negative breast cancer-related mortality in Central and Eastern Europe: Years of life lost and productivity costs. Poster presented at ISPOR, November 2022
- Forestiero F, O’Brien P, Lavelle P, Perry RM, Banhazi J. Economic and humanistic burden of visual impairment and blindness in Brazil: A grey literature review. Poster presented at ISPOR, November 2022
- Bencina G, Chami N, Hughes R, Weston G, Baxter C, Salomonsson S, Demedts I. Indirect costs due to lung cancer-related premature mortality in four European countries. Poster presented at ESMO, September 2022
- McCaughey G, MacCulloch A, Bashorum L, Evans O, Humphries A, Perry R. Burden associated with Fabry Disease and its treatment in 12- to 15-year-olds: Results from an international survey. Poster presented at the RCPCH Conference, June 2022
- Yi Y, Hirst A. Using multi-state modelling for health economic evaluations. Poster presented at ISPOR, May 2022
- Huang M, Haiderali A, Swales O, Yi Y. Budget impact of KEYTRUDA in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for patients with high-risk early-stage triple negative breast cancer in the US. Poster presented at the AMCP conference, March 2022
- Li XJ, Muston D, Ramakrishnan K, Black CM, Hughes R, Weston G, Lucherini S. Budget impact of KEYTRUDA for the treatment of patients with recurrent or metastatic (R/M) and locally advanced (LA) cutaneous squamous cell carcinoma (cSCC) in the United States. Poster presented at the Multidisplinary Head and Neck Cancers Symposium, 2022
- Komakoma l, Yi Y, Hirst A. Exploring the impact of heterogeneity in economic evaluations: Current practice and implications. Poster presented at virtual ISPOR, November 2021
- Song W, Yi Y. Predicting the impact of vaccination strategies in the COVID-19 pandemic using a Susceptible-Exposed-Infectious-Removed model. Poster presented at virtual ISPOR, May 2021
- Huang M, Singhal P, Shinde R, Wilkes S, Nagda N, Yi Y, Lucherini S. Budget impact of Ontruzant for the treatment of breast cancer and gastric cancer in the United States. Poster presented at the San Antonio Breast Cancer Symposium (SABCS), December 2020
- Dimitrova M, Todorov S, Djambazov S, Slavchev G, Swales O, Hughes R, Nagda N, Lucherini S. Estimating the economic and health IMPACT of the PD-1/PD-L1 inhibitor class in Bulgaria. Poster presented at virtual ISPOR, November 2020
- Lehto P, Suvanto T, Aro M, Normand R, Nagda N, Lucherini S. Estimating the economic and health IMPACT of the PD-1/PD-L1 inhibitor class in Finland. Poster presented during virtual ISPOR, November 2020
- Guggisberg P, Huwiler S, Urbinello D, Rachev B, Swales O, Nagda N, Lucherini S. Estimating the budget and health impact of the PD-1/PD-L1 inhibitor class in Switzerland. Poster presented during virtual ISPOR, November 2020
- Yi Y, Lucherini S. Use of cost-effectiveness affordability curves in evaluating cancer drugs in England. Poster presented at ISPOR, November 2019
- Oliver L, Tavella F, Rousseau B. Understanding the humanistic burden and patient impact in non-alcoholic steatohepatitis (NASH). Poster presented at ISPOR, November 2019
- Anstee K, Oldham D, Landels H, Rousseau B. Evaluating the economic and humanistic burden of type 2 diabetes mellitus in emerging markets compared to established markets. Poster presented at ISPOR, November 2019
- Jamadar F, Yi Y, Lucherini S, Heron L. Incorporating the patients’ perspective in economic evaluations of healthcare. Poster presented at ISPOR, November 2019
- Smyrnaios C, Hughes R, Yi Y, Lucherini S. Evaluation of the impact of alternative drug pricing strategies used on the budget impact and cost-effectiveness for products with multiple indications. Poster presented at ISPOR, November 2019
- Hughes R, Hernani M, Lucherini S, Heron L. An economic evaluation of the hospital resourcing implications for the treatment of adverse events. Poster presented at ISPOR, November 2019
- Roediger A, van Bavel J, Pellissier J, Lucherini S, Davies N, Okhuoya P, Rachev B. Budget projections and health impact of the PD-1/PD-L1 inhibitors to inform budget planning – the experience from four European countries. Poster presented at the HTAi conference, June 2019
- Oliver L, Jiandani N, Povsic M, Tavella F, Rousseau B. Do current treatments target the high-burden fibrosis population in non-alcoholic steatohepatitis (NASH)? Poster presented at ISPOR, May 2019
- Wu E, Schenkel B, Povsic M, Wyn R, Hernani M, Kornalska K. Economic evaluations of subcutaneously administered oncology therapies: A health technology assessment (HTA) landscape review. Poster presented at ISPOR, May 2019
- Hughes R, Yi Y. Proposed modelling framework to assess the value of a treatment’s safety profile. Poster presented at ISPOR, May 2019
- Hughes R, Lucherini S, Willke R. How to capture the impact of selection biases in clinical practice on the average efficacy of treatment. Poster presented at ISPOR, May 2019
- Bilder D, Lewis M, Bausell H, Jain M, van Backle J, Jha A, Thomas J. Elicitation of health state utility values in phenylketonuria from a modified Delphi panel. Poster presented at the Society for Inherited Metabolic Disorders (SIMD), April 2019
- Hossain P, Christopoulou D, Anstee K, Okhuoya P. Management of dry eye disease: Results from a survey of healthcare professionals in the United Kingdom. Poster presented at the Medical Contact Lens & Ocular Surface Association (MCLOSA), November 2018
- Hughes R, Lucherini S, Crossley A, Okhuoya P. Multi-comparator ICERs in cost-effectiveness analysis to account for changes in clinical practice after the introduction of a new technology. Poster presented at ISPOR, November 2018
- Palmer T, Collings H, Tavella F. Europe-wide spread of carbapenem-resistant bacteria: Epidemiology and disease burden. Poster presented at ISPOR, November 2018
- Lewis M, Tavella F, Okhuoya P. A scenario analysis of the impact of treatment setting on health care cost and treatment outcomes. Poster presented at ISPOR, November 2018
- Yi Y, Davies N, Tavella F, Okhuoya P. Cost effectiveness and budget impact thresholds in Health Technology Assessment. Poster presented at ISPOR, November 2018
- Ratcliffe A, Lucherini S, Hughes R, Okhuoya P. Multi-comparator ICER: A new framework for cost-effectiveness analysis. Poster presented at the HTAi conference, June 2018
- Van Bavel J, Lucherini S, Rajer M, Jovanovic S, Knzaj Z, Burnik T, Davies N, Toghanian S, Pellissier J, Roediger A. Modelling the budget impact and health outcomes of the anti PD-1/PD-L1 class in cancer care in Slovenia. Poster presented at EUPHA, 2018
- Van Bavel J, Lucherini S, Zielinski C, Walter E, Eckart G, Davies N, Okhuoya P, Pellissier J, Roediger A. Modelling the budget impact and health outcomes of the anti PD-1/PD-L1 class in cancer care in Austria. Poster presented at ISPOR, November 2018
- Van Bavel J, Lucherini S, Vermeersch S, Annemans L, Bento-Abreu A, Davies N, Okhuoya P, Pelliessier J, Roediger A. Assessing the impact of anti PD-1/PD-L1 inhibitors on health and budget in Belgium. Poster presented at ISPOR, November 2018
- Van Bavel J, Lucherini S, Spandonaro F, Polistena B, Dirodi B, Eterno V, Didoni G, Davies N, Pellissier J, Roediger A. Modelling the budget impact and health outcomes of the anti PD-1/PD-L1 class in cancer care in Italy. Poster presented at ISPOR, November 2018
- Wu E, Pellissier J, Bellanca L, Normand R, Hughes R, Ratcliffe A. A contextual model for evaluating the value of multi-indication drugs. Poster presented at the HTAi International Scientific Programme Committee, June 2018
- Yi Y, Lucherini S, Bellanca L, Heron L. Assessing the joint probability of cost-effectiveness and affordability in decision making. Poster presented at ISPOR, November 2017
- Forster R, Ratcliffe A, Lewis M, Crossley A, Lopez Bastida J, Dunlop W. Cost-utility analysis of a novel breath-triggered aerosol inhaler which has been designed to reduce the critical handling error of insufficient inspiratory effort. Poster presented at ISPOR, November 2017
- Hartz S, Walzer S, Dutronc Y, Himatlal Kiri S, Schacht A, Dakin H. Network meta-analysis to evaluate the efficacy of ixekizumab in the treatment of moderate-to-severe psoriasis. Poster presented at ISPOR, November 2016
- Braileanu G, Johnson BC, Ashraf S, Borrill J, Hirst M. Challenges in the health economics of acute pain: A rapid review of the literature. Poster presented at ISPOR, November 2016
- Enstone A, Price G, Viejo I, Dunlop W. Structured review of health economic models in asthma. Poster presented at ISPOR, November 2016
- Enstone A, Panter C, Greaney MH, Bennett B, Penrod JR, Yuan Y. The societal and humanistic burden of small cell lung cancer (SCLC): A systematic review of societal impact and health-related quality of life (HRQoL) literature. Poster presented at ISPOR, November 2016
- Farrington E, Zagorska A, Burnett J. Systematic review of the caregiver burden in melanoma and renal cell carcinoma within Europe. Poster presented at the Society for Melanoma Research (SMR), November 2016
- Rousseau B, Johnson B, Topachevskyi O, Volovyk A. Web-based budget impact and pricing scenarios planning model: Example from the United Kingdom. Poster presented at ISPOR, May 2016
- Nicolai J, Torvinen S, Howard DJ, Miles R, Greaney MH, Comberiati U, Plich A. The budget impact of an inhaler with improved features compared to Spiriva® Handihaler® for the management of chronic obstructive pulmonary disease (COPD) in the UK: Estimated impact on unscheduled healthcare costs and inhaler satisfaction. Poster presented at ISPOR, November 2015
- Nicolai J, Torvinen S, Miles R, Greaney MH, Howard DJ, Plich A. The potential societal cost benefits of increasing patient satisfaction by using an inhaler with improved features compared to Spiriva® Handihaler® for the management of chronic obstructive pulmonary disease (COPD) in the UK. Poster presented at ISPOR, November 2015
- Enstone A, Panter C, Manley Daumont M, Miles R. Societal burden and impact on health related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) in Europe. Poster presented at ISPOR, November 2015
- Fletcher M, Dunlop W, Jha A, Heron L, Van der Molen T, Price D. Burden of asthma on resource and productivity in 6 European countries. Poster presented at the European Respiratory Society Congress, September 2014
- Price D, Dunlop W, Jha A, Heron L, Van der Molen T, Fletcher M. Burden of asthma on resource and productivity in distinct patient clusters. Poster presented at the European Respiratory Society Congress, September 2014
- Hansen T, Streetly M, Laurenson S, Lawrence J, Hulin C. The burden of relapse on European hematologists treating multiple myeloma. Poster presented at the European Hematology Association, June 2014
- Holbrook T, Coles V, Carroll S, Pollard C, Oakley S. The secondary care cost burden to the NHS associated with the 2012 pertussis outbreak in England. Poster presented at the European Society for Pediatric Infectious Diseases, May 2014
- Dunlop W, Heron L, Fox G, Greaney M. Budget impact analysis of a new fixed-dose combination inhaler for a clinical commissioning group within the National Health Service in England. Poster presented at ISPOR, November 2013
- Hansen BB, Kitchen H, Heron L, Gater A, Walmsley S, Pollard C, Højbjerre L, Strandberg-Larsen M. Exploring the humanistic and economic burden of Crohn’s disease: Considerations for novel compounds. Poster presented at ISPOR, May 2013
- Kitchen H, Heron L, Gater A, Walmsley S, Pollard C, Hansen BB, Højbjerre L, Strandberg-Larsen M. Exploring the humanistic and economic burden of Crohn’s Disease: Considerations for novel compounds. Poster presented at the Advances in Inflammatory Bowel Diseases Crohn’s & Colitis Foundation’s National Clinical & Research conference, December 2012
- Gater A, Kitchen H, Heron L, Hansen BB, Højbjerre L, Strandberg-Larsen M. Using clinical outcome assessments and economic data to facilitate patient access in rheumatoid arthritis. Poster presented ISPOR, November 2012
- Novakovic T, Tesic D, Stefanovic D, Medic G, Sovtic D. Guidelines for pharmacoeconomic evaluation for Serbia. Poster presented at ISPOR, November 2011
- Preaud E, Melchior JC, Carles J, Brami M, Duru G, Fontaine E, Hébuterne X, Lukacs B, Zazzo JF, Panis Y, Nitenberg G. Medico-economic analysis of the impact of malnutrition on the post-operative course of colorectal cancer patients. Poster presented at ISPOR, November 2011
- Yi Y, Chouaid C, Vergnenegre A, Bischoff HG, Bergman G, Walzer S, Philips Z. Mixed treatment comparison of bevacizumab-based therapies relative to doublet-chemotherapy combinations to estimate the relative efficacy in progression-free survival for treatment of first-line advanced or metastatic non-small cell lung cancer (NSCLC). Poster presented at ISPOR, November 2010
- Guyot P, Taylor P, Christensen R, Pericleous L, Lebmeier M, Drost P, Bergman G. The cost-effectiveness of Abatacept in combination with methotrexate for the treatment of patient with active RA after an inadequate response to methotrexate in the UK. Poster presented at ISPOR, November 2010
- Tolley K, Goad C, Yi Y, Maroudas P, Thompson G. Utility elicitation study in the UK general public for late stage chronic lymphocytic leukaemia. Poster presented at ISPOR, November 2010
- Rofail D, Kitchen H, Heyes A, Heron L, Sacco P. Cognitive impairment associated with schizophrenia: The humanistic and economic burden. Poster presented at the American Neurological Association, September 2010